We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

193 hedge funds and large institutions have $581M invested in Sage Therapeutics in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 76 increasing their positions, 54 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

363% more call options, than puts

Call options by funds: $10.1M | Put options by funds: $2.18M

41% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 54

5% less funds holding

Funds holding: 204 → 193 (-11)

8.37% less ownership

Funds ownership: 97.3% → 88.92% (-8.4%)

20% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 40

47% less capital invested

Capital invested by funds: $1.1B → $581M (-$516M)

Holders
193
Holders Change
-11
Holders Change %
-5.39%
% of All Funds
2.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
76
Reduced
54
Closed
40
Calls
$10.1M
Puts
$2.18M
Net Calls
+$7.92M
Net Calls Change
+$5.82M

Top Buyers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$11.1M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$8.59M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$8.52M
4
Invesco
Invesco
Georgia
+$7.38M
5
Renaissance Technologies
Renaissance Technologies
New York
+$6.64M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$60.4M
2
State Street
State Street
Massachusetts
-$25.9M
3
Deutsche Bank
Deutsche Bank
Germany
-$12.9M
4
SC
Samlyn Capital
New York
-$11.1M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
PWMG
176
Private Wealth Management Group
New Jersey
$1.03K -$769 -60 -39%
VCM
177
Versant Capital Management
Arizona
$945 +$730 +57 +190%
AA
178
Ancora Advisors
Ohio
$814 – – –
LWCFA
179
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$608 – – –
BTI
180
Blue Trust Inc
Georgia
$560 – – –
CA
181
Continuum Advisory
Idaho
$543 – – –
SPIA
182
Steward Partners Investment Advisory
New York
$543 – – –
Comerica Bank
183
Comerica Bank
Texas
$337 -$3.78K -295 -90%
FFA
184
Farther Finance Advisors
California
$276 +$179 +14 +127%
BIA
185
Bell Investment Advisors
California
$196 – – –
NSIM
186
North Star Investment Management
Illinois
$152 -$1.92K -150 -91%
SC
187
SouthState Corp
Florida
$98 – – –
WWM
188
Wolff Wiese Magana
California
$77 – – –
OP
189
ORG Partners
Indiana
$55 +$64 +5 New
HNB
190
Huntington National Bank
Ohio
$11 -$1.23K -96 -99%
FHA
191
First Horizon Advisors
Tennessee
$11 – – –
AWM
192
Activest Wealth Management
Florida
$11 +$13 +1 New
SC
193
Samlyn Capital
New York
– -$11.1M -594,661 Closed
SFM
194
Soros Fund Management
New York
– -$5.15M -275,000 Closed
Norges Bank
195
Norges Bank
Norway
– -$4.8M -256,052 Closed
CS
196
Candriam SCA
Luxembourg
– -$4.16M -222,000 Closed
IHAM
197
Integral Health Asset Management
New York
– -$3.75M -200,000 Closed
WP
198
Woodline Partners
California
– -$1.96M -104,831 Closed
ECM
199
ExodusPoint Capital Management
New York
– -$1.92M -102,305 Closed
CWM
200
CIBC World Markets
New York
– -$1.87M -100,000 Closed
6 7
8
9 10

SAGE Hedge Fund Activity: Q2 2024 in Review

193 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2024, worth a combined $581M — down 47% from $1.1B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of SAGE and 32 opened new positions — a net loss of 8 holders — while 54 trimmed existing stakes and 76 added.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $11.1M. The largest seller was Wellington Management Group, cutting an estimated $60.4M.

  • 193 institutional investors held Sage Therapeutics (SAGE) as of Q2 2024, down from 204 in Q1 2024.
  • Funds reported $581M of Sage Therapeutics stock for Q2 2024, down 47% quarter-over-quarter.
  • 32 funds opened new Sage Therapeutics positions in Q2 2024 and 40 closed out, a net change of -8 holders.
  • The largest Sage Therapeutics buyer in Q2 2024 was Jacobs Levy Equity Management, an estimated $11.1M added.
  • The largest Sage Therapeutics seller in Q2 2024 was Wellington Management Group, an estimated $60.4M sold.

Based on aggregated 13F filings for Q2 2024.